Future studies using antibody design around AT-1 or anti-CD43 could provide novel therapeutic strategies targeting proliferating CLL cells while leaving the Th cell compartment intact and thus retain valuable adaptive immunity. The gene discussed is SPN; the disease is B-cell chronic lymphocytic leukemia.